Bendamustine

Generic Name
Bendamustine
Brand Names
Belrapzo, Bendeka, Treanda, Vivimusta
Drug Type
Small Molecule
Chemical Formula
C16H21Cl2N3O2
CAS Number
16506-27-7
Unique Ingredient Identifier
9266D9P3PQ
Background

Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...

Indication

Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions
Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
Associated Therapies
-

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

First Posted Date
2021-05-11
Last Posted Date
2021-10-05
Lead Sponsor
Celgene
Registration Number
NCT04882163
Locations
🇬🇧

Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Avera Cancer Institute, Sioux Falls, South Dakota, United States

and more 24 locations

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

First Posted Date
2021-03-22
Last Posted Date
2024-10-28
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
9
Registration Number
NCT04809766
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

DALY II USA/ MB-CART2019.1 for DLBCL

First Posted Date
2021-03-11
Last Posted Date
2024-04-26
Lead Sponsor
Miltenyi Biomedicine GmbH
Target Recruit Count
110
Registration Number
NCT04792489
Locations
🇺🇸

University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States

🇺🇸

Duke University Medical Center - Division of Hematologic Malignancies, Durham, North Carolina, United States

🇺🇸

Stanford University, Stanford, California, United States

and more 19 locations

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

First Posted Date
2021-02-21
Last Posted Date
2021-02-21
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
56
Registration Number
NCT04762745
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Please Select, China

Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)

First Posted Date
2021-02-09
Last Posted Date
2024-11-04
Lead Sponsor
MEI Pharma, Inc.
Target Recruit Count
82
Registration Number
NCT04745832
Locations
🇺🇸

Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center, Springfield, Missouri, United States

🇺🇸

Community Cancer Trials of Utah, Ogden, Utah, United States

🇨🇦

Centre intégré universitaire de santé et de services sociaux de l'Estrie, Sherbrooke, Quebec, Canada

and more 135 locations

A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma

First Posted Date
2020-12-19
Last Posted Date
2024-01-26
Lead Sponsor
Juno Therapeutics, a Subsidiary of Celgene
Target Recruit Count
180
Registration Number
NCT04674813
Locations
🇺🇸

Local Institution - 008, Baltimore, Maryland, United States

🇺🇸

Local Institution - 009, Duarte, California, United States

🇺🇸

Local Institution - 011, New York, New York, United States

and more 7 locations

AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

First Posted Date
2020-12-17
Last Posted Date
2024-02-13
Lead Sponsor
Artiva Biotherapeutics, Inc.
Target Recruit Count
108
Registration Number
NCT04673617
Locations
🇺🇸

University of Alabama, Birmingham, Alabama, United States

🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

🇺🇸

UF Health Shands Cancer Hospital, Gainesville, Florida, United States

and more 18 locations

Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

First Posted Date
2020-12-14
Last Posted Date
2024-10-29
Lead Sponsor
Loxo Oncology, Inc.
Target Recruit Count
250
Registration Number
NCT04666038
Locations
🇨🇦

Princess Margaret Hospital (Ontario), Toronto, Ontario, Canada

🇺🇸

Community Health Network, Indianapolis, Indiana, United States

🇨🇳

Southern Medical University Nanfang Hospital, Guangzhou, Guangdong, China

and more 229 locations

FT819 in Subjects With B-cell Malignancies

First Posted Date
2020-11-16
Last Posted Date
2024-08-02
Lead Sponsor
Fate Therapeutics
Target Recruit Count
54
Registration Number
NCT04629729
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

🇺🇸

Stanford Cancer Institute, Palo Alto, California, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 14 locations
© Copyright 2024. All Rights Reserved by MedPath